Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a […] The post Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer appeared first on Web-Release.

    The seventh edition of the ‘Legislative Week’, the annual flagship event organised by the General Secretariat of the Supreme Legislation Committee in the Emirate of Dubai (SLC), concluded after three days of in-depth dialogue, collaboration, and forward-looking legislative exploration. The event served as both an intellectual forum and a platform for engagement, bringing together a distinguished […] The post 7th edition of ‘Legislative Week’ concludes, setting roadmap for more flexible, proactive legislative ecosystem appeared first on Web-Release.